Votrient FDA Approval History
FDA Approved: Yes (First approved October 19, 2009)
Brand name: Votrient
Generic name: pazopanib
Dosage form: Tablets
Company: GlaxoSmithKline
Treatment for: Renal Cell Carcinoma, Soft Tissue Sarcoma
Votrient (pazopanib) is a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma and advanced soft tissue sarcoma.
Development timeline for Votrient
| Date | Article |
|---|---|
| Apr 26, 2012 | Approval FDA Approves Votrient for Advanced Soft Tissue Sarcoma |
| Oct 19, 2009 | Approval FDA Approves GlaxoSmithKline’s Votrient for Advanced Renal Cell Cancer |
| Oct 5, 2009 | GlaxoSmithKline Receives Unanimous FDA Panel Approval Recommendation for Votrient |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
